back to explore
Stifel Financial Corp. logo

SF

Stifel Financial Corp.
NEW YORK STOCK EXCHANGE, INC.· Financial Services· US· IPO 1983-07-19
$68.64
-0.03 (-0.04%)
last quote
Want the full multi-source brief on SF?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
open in agent
Today
Open
$68.64
High
$69.20
Low
$67.94
Previous close
$68.67
Fundamentals
Market cap
$10.36B
P/E (TTM)
10.61x
P/S (TTM)
1.55x
P/B
2.13x
Gross margin
99.07%
Operating margin
18.57%
Net margin
14.59%
Rev growth (YoY)
8.16%
EPS growth (YoY)
22.96%
ROE
16.07%
52W high
$89.83
52W low
$65.40
Beta
1.05x
Upcoming earnings
next 30 days
2027-01-26in 82 daysafter market
Q4 2026EPS est $1.92Rev est $1618.0M
Recent news
2026-10-28 → 2026-11-04
Yahoo · 2h
Why Stifel Financial (SF) Is Getting Attention Now
Stifel Financial (SF) just expanded its Capital Solutions leadership bench by bringing in seasoned advisers across capital structure, GP-led secondaries, and private capital markets, a shift that puts its investment banking capabilities in sharper focus for investors. Recent developments around Stifel Financial, including the fresh Capital Solutions hires, continued common and preferred dividend d
Yahoo · 6h
Learn Why The Bull Case For Stifel Could Change Following Senior Banking Hires
Stifel Financial's board has declared cash dividends on common and multiple preferred series, and the firm has reported detailed third quarter and year to date 2026 results alongside new senior hires in Capital Solutions and European investment banking. The arrival of seasoned deal makers such as Adam Steinberg, Mickey Brunton, Gavin Kolt and Mark Tweedie points to Stifel Financial sharpening its
Yahoo · 14h
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:40 p.m. ET. A live webcast can be accessed under “E
Yahoo · 14h
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in several upcoming investment conferences in November 2026: Guggenheim 3rd Annual Healthcare Innovation Conference Tuesday, November 10, 2026 at 1:00 pm ET - Fireside Chat Stifel 2026 Healthc
Yahoo · 23h
KBW Appoints Mark Tweedie as Head of European Investment Banking
Mark Tweedie Keefe, Bruyette & Woods, Inc. (“KBW”), a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), today announced the appointment of Mark Tweedie as Managing Director and Head of Investment Banking in Europe. NEW YORK and LONDON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc.
Yahoo · 1d
Stifel Declares Quarterly Common Stock Cash Dividend and Declares Preferred Stock Cash Dividend
ST. LOUIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that its Board of Directors has declared a cash dividend on shares of its common stock of $0.34 per share, payable December 15, 2026, to shareholders of record at the close of business on December 1, 2026. The Board of Directors also declared a quarterly cash dividend on the outstanding shares of its 6.2
Yahoo · 1d
Stifel Expands Leadership in Capital Solutions with Three Senior Hires
Adam Steinberg, Mickey Brunton, and Gavin Kolt Strengthen Capital Structure Advisory, GP-Led Secondaries, and Private Capital Markets CapabilitiesST. LOUIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) (“Stifel”) today announced the recent additions of Adam Steinberg, Mickey Brunton, and Gavin Kolt to senior leadership roles across its Capital Solutions platform. All three a
Yahoo · 5d
Gerresheimer revenue rises 8% in Q3 on demand for drug delivery devices
Investing.com -- Gerresheimer reported third-quarter revenue of €605 million, up 8% year-over-year, while adjusted EBITDA came in at €103 million, down 2.8% YoY, with the adjusted EBITDA margin at 17.1% compared to 19.0% in the prior-year quarter.
This is the free preview

The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.

Start the trial